Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy

Breast Cancer Research and Treatment

Volumn 153, Issue 2, 2015, Pages 435-443

  Ellingson, Marissa S ^a   Hart, Steven N ^a   Kalari, Krishna R ^a   Suman, Vera ^a   Schahl, Kimberly A ^a   Dockter, Travis J ^a   Felten, Sara J ^a   Sinnwell, Jason P ^a   Thompson, Kevin J ^a   Tang, Xiaojia ^a   Vedell, Peter T ^a   Barman, Poulami ^a   Sicotte, Hugues ^a   Eckel Passow, Jeanette E ^a   Northfelt, Donald W ^b   Gray, Richard J ^b   McLaughlin, Sarah A ^c   Moreno Aspitia, Alvaro ^c   Ingle, James N ^a   Moyer, Ann M ^a   Visscher, Daniel W ^a   Jones, Katie ^a   Conners, Amy ^a   McDonough, Michelle ^c   Wieben, Eric D ^a   Wang, Liewei ^d   Weinshilboum, Richard ^a,d   Boughey, Judy C ^a   Goetz, Matthew P ^a   more..

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

Breast cancer; Exome sequencing; Germline mutation pathogenic germline variant; High risk breast cancer; Neoadjuvant chemotherapy; Return of results

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; ATM GENE; BLM GENE; BLOOD SAMPLING; BRCA2 GENE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SUSCEPTIBILITY; CHEK2 GENE; CONTROLLED STUDY; EXOME; FANCA GENE; FANCI GENE; FANCL GENE; FANCM GENE; FEMALE; FH GENE; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE SEQUENCE; GENETIC SCREENING; GENETIC SELECTION; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MLH3 GENE; MUTYH GENE; NONSENSE MUTATION; PALB2 GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST CANCER; TUMOR GENE; TUMOR SUPPRESSOR GENE; WRN GENE; BREAST NEOPLASMS; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DATABASES, GENETIC; EXOME; FEMALE; GENE FREQUENCY; GENES, BRCA1; GENES, BRCA2; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; YOUNG ADULT;

EID: 84940960057     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3545-6     Document Type: Article

References (28)

1. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491:56–65. doi:10.1038/nature11632
2. Bodian DL, McCutcheon JN, Kothiyal P, Huddleston KC, Iyer RK, Vockley JG, Niederhuber JE (2014) Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing. PLoS One 9:e94554. doi:10.1371/journal.pone.0094554
3. Bombard Y, Robson M, Offit K (2013) Revealing the incidentalome when targeting the tumor genome. JAMA 310:795–796. doi:10.1001/jama.2013.276573
4. Castera L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, Brault B, Fouillet R, Goardon N, Letac O, Baert-Desurmont S, Tinat J, Bera O, Dugast C, Berthet P, Polycarpe F, Layet V, Hardouin A, Frebourg T, Vaur D (2014) Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet. doi:10.1038/ejhg.2014.16
5. Dewey FE, Grove ME, Pan C, Goldstein BA, Bernstein JA, Chaib H, Merker JD, Goldfeder RL, Enns GM, David SP, Pakdaman N, Ormond KE, Caleshu C, Kingham K, Klein TE, Whirl-Carrillo M, Sakamoto K, Wheeler MT, Butte AJ, Ford JM, Boxer L, Ioannidis JP, Yeung AC, Altman RB, Assimes TL, Snyder M, Ashley EA, Quertermous T (2014) Clinical interpretation and implications of whole-genome sequencing. JAMA 311:1035–1045. doi:10.1001/jama.2014.1717
6. Ding SL, Yu JC, Chen ST, Hsu GC, Kuo SJ, Lin YH, Wu PE, Shen CY (2009) Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility. Carcinogenesis 30:43–49. doi:10.1093/carcin/bgn233
7. Dorschner MO, Amendola LM, Turner EH, Robertson PD, Shirts BH, Gallego CJ, Bennett RL, Jones KL, Tokita MJ, Bennett JT, Kim JH, Rosenthal EA, Kim DS, Tabor HK, Bamshad MJ, Motulsky AG, Scott CR, Pritchard CC, Walsh T, Burke W, Raskind WH, Byers P, Hisama FM, Nickerson DA, Jarvik GP (2013) Actionable, pathogenic incidental findings in 1,000 participants’ exomes. Am J Hum Genet 93:631–640. doi:10.1016/j.ajhg.2013.08.006
8. Exome Variant Server In: NHLBI GO Exome Sequencing Project (ESP)
9. Gracia-Aznarez FJ, Fernandez V, Pita G, Peterlongo P, Dominguez O, de la Hoya M, Duran M, Osorio A, Moreno L, Gonzalez-Neira A, Rosa-Rosa JM, Sinilnikova O, Mazoyer S, Hopper J, Lazaro C, Southey M, Odefrey F, Manoukian S, Catucci I, Caldes T, Lynch HT, Hilbers FS, van Asperen CJ, Vasen HF, Goldgar D, Radice P, Devilee P, Benitez J (2013) Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One 8:e55681. doi:10.1371/journal.pone.0055681
10. Johnston JJ, Rubinstein WS, Facio FM, Ng D, Singh LN, Teer JK, Mullikin JC, Biesecker LG (2012) Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet 91:97–108. doi:10.1016/j.ajhg.2012.05.021
11. Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH, Bontenbal M, Collee JM, Menke-Pluijmers MB, Martens JW, Seynaeve C (2012) The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer 118:899–907. doi:10.1002/cncr.26351
12. Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, McGuire V, Ladabaum U, Kobayashi Y, Lincoln SE, Cargill M, Ford JM (2014) Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32:2001–2009. doi:10.1200/JCO.2013.53.6607
13. Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, Maglott DR (2014) ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 42:D980–985. doi:10.1093/nar/gkt1113
14. Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK, Salovaara R, Herva R, Koivisto PA, Vierimaa O, Aittomaki K, Pukkala E, Launonen V, Aaltonen LA (2006) Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet 43:523–526. doi:10.1136/jmg.2005.036400
15. Lindor NM, McMaster ML, Lindor CJ, Greene MH (2008) Concise handbook of familial cancer susceptibility syndromes—second edition. J Natl Cancer Inst Monogr 38:1–93. doi:10.1093/jncimonographs/lgn001
16. Mwenifumbo JC, Marra MA (2013) Cancer genome-sequencing study design. Nat Rev Genet 14:321–332. doi:10.1038/nrg3445
17. Online Mendelian Inheritance in Man (OMIM®) McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore
18. Pasche B, Absher D (2011) Whole-genome sequencing: a step closer to personalized medicine. JAMA 305:1596–1597. doi:10.1001/jama.2011.484
19. Prokofyeva D, Bogdanova N, Dubrowinskaja N, Bermisheva M, Takhirova Z, Antonenkova N, Turmanov N, Datsyuk I, Gantsev S, Christiansen H, Park-Simon TW, Hillemanns P, Khusnutdinova E, Dork T (2013) Nonsense mutation p. Q548X in BLM, the gene mutated in Bloom’s syndrome, is associated with breast cancer in Slavic populations. Breast Cancer Res Treat 137:533–539. doi:10.1007/s10549-012-2357-1
20. Rennert G, Lejbkowicz F, Cohen I, Pinchev M, Rennert HS, Barnett-Griness O (2012) MutYH mutation carriers have increased breast cancer risk. Cancer 118:1989–1993. doi:10.1002/cncr.26506
21. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, Lyon E, Ward BE (2008) ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 10:294–300. doi:10.1097/GIM.0b013e31816b5cae
22. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29:308–311
23. Solyom S, Winqvist R, Nikkila J, Rapakko K, Hirvikoski P, Kokkonen H, Pylkas K (2011) Screening for large genomic rearrangements in the FANCA gene reveals extensive deletion in a Finnish breast cancer family. Cancer Lett 302:113–118. doi:10.1016/j.canlet.2010.12.020
24. Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K (2014) Cancer genomics and inherited risk. J Clin Oncol 32:687–698. doi:10.1200/JCO.2013.49.7271
25. Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper DN (2009) The Human Gene Mutation Database: 2008 update. Genome Med 1:13. doi:10.1186/gm13
26. Szabo C, Masiello A, Ryan JF, Brody LC (2000) The breast cancer information core: database design, structure, and scope. Hum Mutat 16:123–131. doi:10.1002/1098-1004(200008)
27. Thompson ER, Doyle MA, Ryland GL, Rowley SM, Choong DY, Tothill RW, Thorne H, Barnes DR, Li J, Ellul J, Philip GK, Antill YC, James PA, Trainer AH, Mitchell G, Campbell IG (2012) Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet 8:e1002894. doi:10.1371/journal.pgen.1002894
28. Wang Z, Xu Y, Tang J, Ma H, Qin J, Lu C, Wang X, Hu Z, Shen H (2009) A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women. Breast Cancer Res Treat 118:169–175. doi:10.1007/s10549-009-0327-z